• Aged 18-75 years old, regardless of gender；

• Surgically resectable locally advanced squamous cell carcinoma of the esophagus confirmed by histology or cytology (pre-treatment clinical stage cT1b-cT2, N+ or cT3-cT4a, ANY N according to the 8th edition of AJCC staging);

• Presence of measurable and/or non-measurable lesions as defined by the criteria for evaluating the efficacy of solid tumors (RECIST v1.1);

• No prior antitumor therapy for esophageal cancer, including chemotherapy, radiotherapy (including planned radiotherapy during the study period), hormone therapy, and immunotherapy;

• ECOG PS 0 to 1 point;

• No contraindication to surgery as evaluated by various organ function tests;

• Prior to treatment, the following laboratory tests to confirm that bone marrow, liver and kidney function meet the requirements for participation in the study (requiring no blood transfusion or use of hematopoietic stimulating factors (including G-CSF, GM-CSF , EPO, and TPO, etc.) within 14 days prior to screening):

‣ Hemoglobin ≥ 90 g/L;

⁃ White blood cell count ≥ lower limit of laboratory normal;

⁃ Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;

⁃ Platelet count ≥100×109/L;

⁃ Total bilirubin ≤ 1.5 x upper limit of normal (ULN);

⁃ Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN;

⁃ Prothrombin time ≤ 16 seconds and International Normalized Ratio (INR) ≤ 1.5 x ULN;

⁃ Creatinine ≤ 1.5 x ULN and Cr clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula);

• Must understand and voluntarily sign an informed consent form.